Slingshot Biosciences raises $23M for synthetic cell platform

By The Science Advisory Board staff writers

Slingshot Biosciences announced the closing of $23 million in series A financing to fund the company's synthetic cell products portfolio.

As part of the funding, Adam Wieschhaus, PhD, director at Northpond Ventures, and Corey Ritter, senior associate at Arch Venture Partners, will join Slingshot's board of directors. Both companies took part in leading the investment initiative.

Slingshot will also invest in its broader adoptive cell therapy and therapeutics platform with this growth financing, the company said. The company is aiming its technology at adoptive cell therapy tools and therapeutic modalities that can use its synthetic cell engineering platform.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?